CYAD Stock Price, News & Analysis

Celyad Oncology SA announced a double voting right for Tolefi SA’s shares effective May 3, 2021, increasing the total number of voting rights to 17,373,181. The company's total share capital amounts to €52,211,200.33, consisting of 12,637,131 shares with single voting rights and 2,368,025 shares with double voting rights. The disclosure is in line with the Belgian law regarding major participations in listed companies.

Celyad Oncology has completed two capital increases, issuing 300,000 new shares to Lincoln Park Capital Fund, LLC, increasing its share capital to 52,211,200.33 EUR and total shares to 15,005,156. The company reported 14,932,832 shares with single voting rights and 72,324 with double voting rights. Total voting rights reached 15,077,480, with a total of 1,802,756 warrants outstanding. These actions comply with Belgian regulations on major participations in publicly traded firms.

Celyad Oncology (Euronext & Nasdaq: CYAD) announced the appointment of Dr. Charles Morris as Chief Medical Officer, aiming to enhance its medical and clinical strategies. Dr. Morris, with over 20 years of experience in oncology drug development, previously held significant roles at Radius Health and Cephalon, contributing to multiple drug approvals. His expertise is expected to be pivotal during a crucial year for the company, which anticipates several important data readouts regarding its allogeneic CAR T therapies.

Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced its participation in several upcoming conferences in April 2021, focusing on CAR T therapies for cancer. Key events include the Cell & Gene Meeting on the Mediterranean (April 6-9), where CEO Filippo Petti will present, and the 2021 Virtual Wells Fargo Biotech Corporate Access Day on April 8. The company is dedicated to developing innovative CAR T therapies for hematological malignancies and solid tumors, supported by funding from the Walloon Region of Belgium.

Celyad Oncology (CYAD) announced a capital increase of 200,000 new shares to Lincoln Park Capital Fund on March 29, 2021. The total share capital now amounts to 50,123,200.33 EUR, represented by 14,405,156 shares. Following this transaction, the total number of shares with single voting rights stands at 14,332,832, while double voting shares total 72,324.

The dilutive impact of this share issuance increases the total diluted share count to 16,139,595, including warrants. This adjustment complies with Belgian regulations regarding major participations.

Celyad Oncology SA (CYAD) reported no safety concerns in the Phase 1 IMMUNICY-1 trial for its lead shRNA-based CAR T candidate, CYAD-211, aimed at treating relapsed/refractory multiple myeloma. Enrollment in the second dose cohort has begun, with additional data anticipated in Q2 2021. The company is also progressing with its alloSHRINK trial for CYAD-101 in advanced metastatic colorectal cancer, with preliminary data expected soon. As of December 31, 2020, Celyad had a cash position of €17.2 million ($21.2 million) and entered a $40 million equity purchase agreement to support operations.

Celyad Oncology will announce its full year 2020 financial results on March 24, 2021. A conference call for discussion will take place on March 25 at 1 p.m. CET / 8 a.m. ET. The company focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, including allogeneic and autologous candidates targeting hematological malignancies and solid tumors. Celyad has received funding from the Walloon Region to support its CAR T programs. The company warns that known and unknown risks may impact its financial condition and business outlook.

Celyad Oncology SA (Euronext & Nasdaq: CYAD) has announced participation in two upcoming virtual investor conferences in March 2021. The H.C. Wainwright Global Life Sciences Conference will occur from March 9 to March 10, while BioCapital Europe is scheduled for March 11. The company is focused on developing CAR T therapies for cancer, including both allogeneic and autologous candidates. Celyad has received funding from the Walloon Region to advance its programs and emphasizes ongoing work towards clinical trials, despite challenges posed by the COVID-19 pandemic.

Celyad Oncology SA (CYAD) announced a capital increase on January 7, 2021, issuing 262,812 new shares to Lincoln Park Capital Fund, LLC. The company's total share capital now stands at 49,427,200.33 EUR, represented by 14,132,832 shares. This transaction increases the total number of shares to 14,205,156, with diluted shares reaching 15,693,162. The press release adheres to Belgian law regarding major shareholding disclosures. Celyad focuses on developing CAR T cell therapies for cancer.